Acceleron Pharma (NASDAQ: RGNX) and Regenxbio (NASDAQ:RGNX) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, dividends, analyst recommendations and valuation.
Institutional & Insider Ownership
88.7% of Acceleron Pharma shares are held by institutional investors. Comparatively, 80.8% of Regenxbio shares are held by institutional investors. 3.0% of Acceleron Pharma shares are held by insiders. Comparatively, 16.9% of Regenxbio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This is a breakdown of current ratings for Acceleron Pharma and Regenxbio, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Acceleron Pharma currently has a consensus price target of $51.50, suggesting a potential upside of 3.37%. Regenxbio has a consensus price target of $81.08, suggesting a potential upside of 22.57%. Given Regenxbio’s stronger consensus rating and higher possible upside, analysts clearly believe Regenxbio is more favorable than Acceleron Pharma.
Risk & Volatility
Acceleron Pharma has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500. Comparatively, Regenxbio has a beta of -1.16, suggesting that its stock price is 216% less volatile than the S&P 500.
This table compares Acceleron Pharma and Regenxbio’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares Acceleron Pharma and Regenxbio’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Acceleron Pharma||$13.48 million||170.01||-$108.45 million||($2.68)||-18.59|
|Regenxbio||$10.39 million||205.71||-$73.16 million||($2.45)||-27.00|
Regenxbio has lower revenue, but higher earnings than Acceleron Pharma. Regenxbio is trading at a lower price-to-earnings ratio than Acceleron Pharma, indicating that it is currently the more affordable of the two stocks.
Regenxbio beats Acceleron Pharma on 9 of the 14 factors compared between the two stocks.
About Acceleron Pharma
Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis. The company is also developing and sotatercept for the treatment of patients with pulmonary arterial hypertension. In addition, the company is developing ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with facioscapulohumeral dystrophy and Charcot-Marie-Tooth disease; and ACE-2494, which is in Phase I clinical trials for the treatment of systemic muscle disorders. It has a collaboration, license, and option agreement with Celgene Corporation. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform. The company's lead product candidate is RGX-314 for the treatment of wet age-related macular degeneration. It is also developing RGX-501 for the treatment of homozygous familial hypercholesterolemia, which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; and RGX-111 to treat the neurological symptoms of Mucopolysaccharidosis Type I that uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system (CNS). In addition, the company engages in the development of RGX-121 for the treatment of neurological symptoms of Mucopolysaccharidosis Type II, which uses the AAV9 vector to deliver the human iduronate-2-sulfatase gene to the CNS. Further, it licenses its NAV technology platform to other biotechnology companies. The company was formerly known as REGENX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.